Ironwood Pharmaceuticals (IRWD) 10-Q2019 Q1 Quarterly report

Filed: 2 May 19, 4:06pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: accommodate, Amy, Bausch, Binney, biopharmaceutical, breakthrough, Cambridge, cap, center, colocation, competitor, Cyclerion, deep, disregard, drew, Fanucci, fault, feet, floor, free, front, harnessing, home, inclusive, indemnification, indemnity, join, judge, judicial, landlord, LLC, Mallon, Marsha, master, McGuire, migrated, MOTEGRITY, nonrefundable, occupied, opponent, original, originally, payroll, people, pilot, power, procurement, prucalopride, Rebate, referenced, reintroduced, rentable, rental, ROU, Schulman, Shire, square, sublease, subsidiary, surrendered, swing, teaching, tegaserod, temporarily, Terrance, unconstitutional, ZELNORM

Removed: accelerating, accrual, achalasia, acute, addressing, advancement, akin, allopurinol, amortizing, analog, analyze, approach, assessing, assessment, assistance, assured, automatically, blood, boosting, bringing, cancer, cell, CFDA, channel, charged, Clarifying, collaborator, collectability, collected, Cologuard, colorectal, concentration, consumed, Consummation, consumption, contemplated, contracted, contractor, contrary, creatinine, cumulative, cycle, damaged, deduct, DELZICOL, demonstrated, demonstrating, depict, determinable, diabetic, differentiating, directed, Directive, disagree, discretion, dissolution, DNA, dual, Dysregulation, earn, educated, ejection, eluxadoline, enhancement, Exact, existed, Expensing, explain, extinguishment, fibrotic, forecasted, fraction, gained, generating, gout, headache, heart, heightened, HFpEF, holding, hyperuricemia, imposing, incorrectly, influenza, inhibitor, initiating, intestine, invoice, kidney, labeled, leveraging, linked, located, measure, medically, merger, motion, multidimensional, nephropathy, nitric, noninvasive, notify, notifying, offered, outflow, overcome, overhead, oversee, oxidase, oxide, paired, partial, passage, passed, pathway, pattern, payor, persuasive, pharmacological, pharmacy, polymorphic, poorly, preclude, predominant, presence, preserved, produced, progressing, prompt, Recognizing, reconciling, recoverable, recovery, reevaluate, regime, reliable, reliably, remitted, rendered, resell, reserve, residual, responded, restate, retail, retaining, retrospectively, returned, returning, revalued, screening, secretary, separable, separated, serum, shelf, shipped, shipping, sickle, signaling, silent, simulation, stool, strict, substantive, summarize, supplier, supported, survive, symptom, systematically, tablet, talent, targeting, tiered, title, TPE, transplant, tumor, unamortized, uncontrolled, undelivered, unit, unopened, unprescribed, unrealized, unrecognized, unsatisfied, unvested, unwilling, uric, venue, visceral, visibility, voluntary, vote, VSOE, warehouse, wholesale, xanthine, XOI

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated IRWD transcripts

IRWD similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Ironwood Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark Mallon, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ MARK MALLON
Mark Mallon
Chief Executive Officer
May 2, 2019

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.